1. Adams, G. P., McCartney, J. E., Tai, M. S., Oppermann, H., Huston, J. S., Stafford, W. F., Bookman, M. A., Fand, I., Houston, L. L. & Weiner, L. M. (1993). Highly specific in vivo tumor targeting by monovalent and divalent forms of 741F8 anti-c-erbB-2 single-chain Fv. Cancer Res 53: 4026–4034.
2. Barth, S., Huhn, M., Wels, W., Diehl, V. & Engert, A. (1998). Construction and in vitro evaluation of RFT5(scFv)-ETA’, a new recombinant single-chain immunotoxin with specific cytotoxicity toward CD25+ Hodgkin-derived cell lines. Int J Mol Med 1: 249–256.
3. Bradbury, A., Ruberti, F., Werge, T., Amati, V., Di Luzio, A., Gonfloni, S., Hoogenboom, H. R., Piccioli, P., Biocca, S. & Cattaneo, A. (1995). The cloning of hybridoma V regions for their ectopic expression in intracellular and intercellular immunization. In Antibody Engineering, 2nd edn. Borrebaeck COxford University Press: New York 295 .
4. Dower, W. J., Miller, J. F. & Ragsdale, C. W. (1988). High efficiency transformation of E. coli by high voltage electroporation. Nucleic Acids Res 16: 6127–6145.
5. Dürkop, H., Latza, U., Hummel, M., Eitelbach, F., Seed, B. & Stein, H. (1992). Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin’s disease. Cell 68: 421–427.